Report Id: SNS/HC/2427 | July 2022 | Region: Global | 140 Pages
Nanomedicine Market Overview:
The Nanomedicine Market Size was valued at USD 121.5 billion in 2021, and expected to reach USD 238.4 billion by 2028, and grow at a CAGR of 10.1% over the forecast period 2022-2028.
The area of medicine known as nanomedicine uses nanotechnology to treat and prevent disease. In order to diagnose, deliver, sense, or operate upon a living creature, nanomedicine uses nanoscale materials like biocompatible nanoparticles and nanorobots.
Due to their small size, nanomaterials have unique physicochemical features that set them apart from their bulk chemical counterparts. These characteristics significantly improve a number of chances for medication development. The physicochemical characteristics of the nanoformulation have the potential to more easily cross biological barriers, have toxic properties, and have persistence in the environment and the human body. These properties can change pharmacokinetics, like absorption, elimination, metabolism and distribution.
Top-down and bottom-down strategies are used in the pharmaceutical manufacture of nanomaterials. A large substance is broken down into one or more smaller bits using mechanical or chemical energy in the top-down process. On the other hand, the bottom-up method begins with atomic or molecular species that enable precursor particles to grow in size through chemical reaction.
The expansion of nanorobot research and development
Chronic and infectious diseases are becoming more prevalent globally.
Strong Regulatory Standards
An increase in the sale of nanomedicines and advancements in healthcare infrastructure in emerging economies.
Lengthy approval procedures and several dangers related to nanomedicines
IMPACT OF COVID-19
The need for nanomedicines to cure a wide range of illnesses has increased as a result of the COVID-19 pandemic. The development of new approaches for the detection, diagnosis, and treatment of the COVID-19 virus and other viral infections was made possible by the development of nanomedicine applications. The development of nano-based materials such as disinfectants, personal protective equipment, diagnostic systems, and barrier systems for medical treatment and vaccine research allowed for the management of COVID-19. This has an impact on the market since it raises interest in nanomedicines. Overall, it has been claimed that COVID-19 has had a positive effect on the market for nanomedicine. This resulted from an increase in the need for nanomedicines to treat conditions that resemble cancer. Additionally, as a result of an increase in nanomedicine R&D activities across the board, industry participants have observed a rise in investments in materials and resources.
Furthermore, the nanomedicine industry was mostly unaffected in other MedTech firms that were wiped out by the COVID-19. This is primarily caused by how serious the medical conditions that nanomedicines are designed to treat are. In order to maintain their quality of life, people who had been prescribed nanomedicines before to the pandemic continued to do so. The need for nanomedicine to identify life-threatening diseases early has driven the market's sustained growth, despite the fact that the number of new patients getting nanomedicines marginally fell during the pandemic's worst months.
Diagnostic and therapeutic applications make up the global nanomedicine market. Due to the technological development of nanomedicine, increase in adoption of nanomedicine, rise in prevalence of chronic diseases, and increase in the number of advanced and effective products in the market, the treatment segment was the largest contributor to the global market and is expected to continue to dominate during the forecast period.
Drug delivery, diagnostic imaging, vaccinations, regenerative medicine, implants, and other products are segments of the worldwide nanomedicine market. Due to the rising incidence of diseases like cancer and the COVID-19 virus as well as growing public awareness of the potential uses for nanomedicines, the drug delivery segment was the largest contributor to the global market and is predicted to continue to hold a dominant position during the forecast period.
Clinical cardiology, orthopedics, neurology, urology, ophthalmology, immunology, clinical oncology, infectious disorders, and others are the subsets of the global nanomedicine market. The clinical oncology segment, which accounted for a major portion of the global market, is expected to continue to dominate over the forecast period owing to the rise in cancer and rising disposable income.
Some of the major key players are as follows: Pfizer Inc., Mallinckrodt plc, Teva Pharmaceuticals Ltd., Merck & Co., Inc., Johnson & Johnson, Abbott Laboratories, Invitae Corporation, General Electric Company, Leadient BioSciences Inc., DiaSorin S.p.A., and other players.
The global nanomedicine market was dominated by North America and this dominance is expected to continue during the forecast period. This is due to an increase in the prevalence of fatal diseases, an increase in the demand for nanomedicines, the availability of high-end healthcare facilities with qualified medical personnel, an increase in research and development activities with a significant presence of key players, and an increase in government investment in healthcare. However, Asia Pacific is expected to have the highest growth rate during the projection.
Rest of Europe
Rest of Asia-Pacific
The Middle East & Africa
Rest of Middle East & Africa
Rest of Latin America
|Market Size in 2021||US$ 121.5 Billion|
|Market Size by 2028||US$ 238.4 Billion|
|CAGR||CAGR of 10.1% From 2022 to 2028|
|Report Scope & Coverage||Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook|
|Key Segments||• By MODALITY (Diagnostics, Treatment)
• By APPLICATION (Drug Delivery, Diagnostic Imaging, Vaccines, Regenerative Medicine, Implants)
• By INDICATION (Clinical Oncology, Infectious Diseases, Clinical Cardiology, Orthopedics, Neurology, Urology, Ophthalmology, Immunology)
|Regional Analysis/Coverage||North America (USA, Canada, Mexico), Europe
(Germany, UK, France, Italy, Spain, Netherlands,
Rest of Europe), Asia-Pacific (Japan, South Korea,
China, India, Australia, Rest of Asia-Pacific), The
Middle East & Africa (Israel, UAE, South Africa,
Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
|Company Profiles||Pfizer Inc., Mallinckrodt plc, Teva Pharmaceuticals Ltd., Merck & Co., Inc., Johnson & Johnson, Abbott Laboratories, Invitae Corporation, General Electric Company, Leadient BioSciences Inc., DiaSorin S.p.A., and other players.|
|Key Drivers||• The expansion of nanorobot research and development
• Chronic and infectious diseases are becoming more prevalent globally.
|RESTRAINTS||• Strong Regulatory Standards|
Frequently Asked Questions (FAQ) :
Ans. Nanomedicine Market Size was valued at USD 121.5 billion in 2021, and expected to reach USD 238.4 billion by 2028, and grow at a CAGR of 10.1% over the forecast period 2022-2028.
Ans. The area of medicine known as nanomedicine uses nanotechnology to treat and prevent disease. In order to diagnose, deliver, sense, or operate upon a living creature, nanomedicine uses nanoscale materials like biocompatible nanoparticles and nanorobots.
Ans. Key drivers of the Nanomedicine Market is the expansion of nanorobot research and development, and Chronic and infectious diseases are becoming more prevalent globally
Ans. Drug Delivery, Diagnostic Imaging, Vaccines, Regenerative Medicine, and Implants are the sub segments of Nanomedicine market.
Ans. Diagnostic and therapeutic applications make up the global nanomedicine market.
Table of Contents
1.1 Market Definition
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
4. Impact Analysis
4.1 COVID 19 Impact Analysis
4.2 Impact of Ukraine ware
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Nanomedicine Market Segmentation, By Modality
9. Nanomedicine Market Segmentation, By Application
9.1 Drug Delivery
9.2 Diagnostic Imaging
9.4 Regenerative Medicine
10. Nanomedicine Market Segmentation, By Indication
10.1 Clinical Oncology
10.2 Infectious Diseases
10.3 Clinical Cardiology
11. Regional Analysis
11.2 North America
11.3.6 The Netherlands
11.3.7 Rest of Europe
11.4.2 South Korea
11.4.6 Rest of Asia-Pacific
11.5 The Middle East & Africa
11.5.3 South Africa
11.6 Latin America
11.6.3 Rest of Latin America
12.1 Pfizer Inc.
12.1.2 Products/ Services Offered
12.1.3 SWOT Analysis
12.1.4 The SNS view
12.2 Mallinckrodt plc
12.3 Teva Pharmaceuticals Ltd.
12.4 Merck & Co., Inc.
12.5 Johnson & Johnson
12.6 Abbott Laboratories
12.7 Invitae Corporation
12.8 General Electric Company
12.9 Leadient BioSciences Inc.
12.10 DiaSorin S.p.A.
13.1 Competitive Benchmark
13.2 Market Share analysis
13.3 Recent Developments
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.